Marked prolongation of QRS duration after initiation of dronedarone therapy
Abstract:
Overview
Dronedarone is a relatively new antiarrhythmic drug and is held to be less proarrhythmic than comparable compounds, although its proarrhythmia potential in humans has not been sufficiently evaluated. We describe a so far unreported dronedarone effect, namely a significant alteration of both the morphology and the duration of the QRS complex on the electro cardiogram in a 41-year old patient with symptomatic paroxysmal atrial fibrillation.
Keywords
Adverse drug events, Antiarrhythmic drugs, Atrial fibrillation, Dronedarone.
Article:
Article Information:
Correspondence
Samir M. Said, Otto-von-Guericke University University Hospital, Centre of Internal Medicine Division of Cardiology Leipziger Str. 44 39120 Magdeburg, Germany samir.said@med.ovgu.de